Indication
Head and Neck Tumors
2 clinical trials
3 products
1 drug
Clinical trial
A Prospective Single-center, Single-arm Clinical Study of the PD-1 Inhibitor Tislelizumab Combined With APF Sequential Surgery or Radical Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Head and Neck TumorsStatus: Recruiting, Estimated PCD: 2024-06-07
Product
TislelizumabClinical trial
Phase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck CancersStatus: Not yet recruiting, Estimated PCD: 2029-01-01
Product
[212Pb]VMT-alpha-NETProduct
[203Pb]VMT-alpha-NETDrug
68Ga-DOTATATE